News

Migrants and refugees frequently experience substantial barriers when accessing healthcare services, including language difficulties, limited knowledge of healthcare structures and administrative complexity due to cultural differences and low health literacy.

These barriers may contribute to delayed care, poorer health outcomes, and increased healthcare costs. Health navigators have emerged as a community-based support model intended to address these challenges by providing culturally sensitive guidance, orientation, and peer-to-peer support.

This mixed-method review aimed to examine the role and impact of health navigators for migrants and refugees.

Tisotumab vedotin is an antibody-drug conjugate consisting of a monoclonal antibody linked to a microtubule inhibitor. The antibody specifically binds to tissue factor on the cell surface; the complex is internalised, and the cytotoxic agent is released, leading to the death of cancer cells. Tisotumab vedotin is administered as monotherapy for the treatment of adult patients with cervical cancer whose disease has progressed during or after systemic therapy. It is given as an intravenous infusion every three weeks until disease progression or unacceptable toxicity occurs. The innovaTV 301 study demonstrated an overall survival (OS) benefit for tisotumab vedotin (n=253) compared with chemotherapy (n=249; HR 0.70, 95% CI 0.54-0.89), with a median OS increase of approximately 2 months. Progression-free survival was also improved by about 1.3 months. However, no clear improvement in quality of life was demonstrated. Treatment-emergent adverse events (TEAEs) were common in both treatment arms, but grade >=3 TEAEs and serious adverse events occurred less frequently with tisotumab vedotin. Ocular events occurred significantly more frequently. Regarding the quality of evidence, there are concerns about the risk of bias, particularly with respect to missing data and the reporting of outcomes. Tisotumab vedotin received approval from the European Commission in March 2025.

Teplizumab (TEIZEILD®) is a monoclonal anti-CD3 antibody that modulates the autoimmune response in stage 2 type 1 diabetes by inhibiting autoreactive T cells and preserving endogenous insulin secretion. This single intravenous 14-day infusion course is indicated for adults and children aged 8 years and older with stage 2 T1D to delay progression to stage 3. In the randomised, placebo-controlled phase 2 TN-10 trial (n=76, median follow-up: 24.5 months), the median time to T1D diagnosis was 48.4 months with teplizumab versus 24.4 months with placebo (p<0.01). C-peptide levels were significantly higher in the teplizumab group (1.94 vs 1.72 pmol/ml; p<0.01). Regarding safety, adverse events occurred in nearly all patients; the most common were haematological disorders (75%, predominantly lymphopenia) and skin reactions (36%). Severe adverse events (grade ?3) occurred mainly within the first 30 days and were largely reversible. The available evidence is limited by a small sample size, absence of quality-of-life data, and limited long-term follow-up. Teplizumab received marketing authorisation from the European Commission in early January 2026.

Substance use disorders are among the world's greatest public health challenges. The EU project FALCO examined which outcome instruments are suitable for the long-term evaluation of music therapy in the treatment of substance use disorders. Instruments measuring stable constructs – such as depression, problem severity, and self-efficacy – were identified as most appropriate. Service user interviews revealed social parameters as the most frequently mentioned aspect of recovery, with children, pets, and employment as key facilitators. Validated instruments exist, but gaps remain. Future research should prioritise long-term studies, core outcome sets, and culturally adapted instruments incorporating social and socioeconomic dimensions.

Austria currently lacks a formally endorsed national health economic evaluation guideline (HEEG) with detailed methodological specifications, which hinders the broader application of health economic evidence in reimbursement decisions. This review systematically examined mandatory HEEGs from high-income countries to identify common standards for conducting health economic evaluations, synthesising findings into a structured overview of methodological convergence and divergence at the international level. The results are intended to support Austrian policymakersand HTA stakeholders in developing a nationally tailored, methodologically robust guideline applicable across a wide range of healthcare decision-making contexts.

Anxiety and depressive disorders account for a significant proportion of the global mental health burden. Treatment challenges in antidepressant therapy have stimulated interest in adjunctive nutritional interventions, such as B vitamins, due to their role in neurobiological processes relevant to mood regulation. However, existing systematic reviews have not focused specifically on adjunctive regimens combining multiple B vitamins with antidepressants. Consequently, this systematic review aimed to evaluate the efficacy and safety of combining a vitamin B complex (?2 B vitamins) with antidepressant medication to improve symptom severity in depression and anxiety.